The cell signaling market is expected to register a CAGR of nearly 6.2% during the forecast period, with a revenue of approximately USD 3,455 million in 2020, and it is expected to reach USD 4,945 million by 2026.
The COVID-19 is likely to have a profound impact on the market studied. A new study published in the journal News Medical, "SARS-CoV-2 spike protein triggers cell signaling pathways in lung vascular cells" in October 2020 stated that vascular cells in the lung tissue begin to secrete signaling growth factors when exposed to just the spike protein of severe acute respiratory syndrome coronavirus without the rest of the viral components. As this signaling mechanism is potentially linked to worse outcomes in this situation, these findings could indicate new targets for the development of therapeutic agents. Thus, the high utility of cell signaling models for research about COVID-19 and respiratory diseases is expected to offer significant growth opportunities to the market.
The major factors for the growth of the cell signaling market include the rising incidence of chronic diseases, increased funding for cell-based research, and technological advancements in cell-based research instruments. There is rising funding for cell-based research across the world.
For instance, according to the data available on the portal for the National Institutes of Health (NIH), an estimated USD 1,626 million was granted for stem cell research in the fiscal year 2019. In contrast, the actual fund grants for stem cell research in the fiscal year 2018, amounted to USD 1,748 million.
Similar increments in funding grants were observed for research in the areas of embryonic stem cell and induced pluripotent stem cell. Similar positive trends in the increment of fund grants have been observed in the European Union for cell-based research. Consequently, the increasing participation of government for the development of cell-based research, in the form of incremental funding, is expected to drive the growth of the market studied. Other factors contributing to the growth of the market studied include the increasing incidence of chronic diseases and technological advancements in cell-based research instruments.
However, high cost of cell signaling systems and ethical issues related to embryonic stem cell signaling research is likely to hindered the market growth.
Key Market Trends
AKT Signaling Pathway is Expected to Register Good Growth Over the Forecast Period
The AKT signaling pathway, also known as the survival pathway, is responsible for the increased proliferation, loss of apoptosis signaling, and cell growth. The AKT signaling pathway is the most commonly dysregulated pathway in the most prevalent forms of cancer. A number of drugs have been designed, based on the rationale that inhibition of AKT pathway could help in achieving therapeutic results. A number of drugs based on AKT signaling are currently in various stages of clinical trials.
In the treatment of the advanced-stage COVID-19 patients, Akt found as a potential therapeutic target. Its inhibition will potentially suppress the cytokine storm, fibroproliferation, pathological inflammation, and platelet activation associated with COVID-19. It also promotes resolution and prevents scarring in injured lungs. As per the study published "Akt a viable option to treat advanced-stage COVID-19 patients" in 2020, reported that pharmacological inhibition of Akt has also been reported to inhibit angiotensin-converting enzyme 2 (ACE2) expression, a receptor for the virus entry into the lung cells, targeting Akt for COVID-19 looks a viable option. Thus, the segment is likely to have positive impact on the segment studied.
AKT inhibitors can be classified into four categories. The first category consists of competitive inhibitors of the ATP binding site on the kinase domain. The second category is allosteric inhibitors of the AKT kinase domain. Other similar categories of the drug exist, which are based on the regulation of AKT pathway. Overall, the market for the AKT signaling pathway has the largest share, due to the comprehensive list of pipeline drugs, which are based on the regulation of AKT signaling.
Over the forecast period, this market is expected to increase, as commercial diagnostic tests are expected to emerge, based on down-regulation of the AKT pathway. This is likely to be employed as a biomarker in cancer diagnosis.
North America is Expected to Dominate the Market Over the Forecast Period
North America is found to hold a major share of the cell signaling market and is expected to show a similar trend over the forecast period, without significant fluctuations. The cell signaling market is expected to witness numerous growth opportunities during the pandemic, with cell signaling pathways being utilized as experimental virology platforms to study the immune responses and infectivity of SARS-CoV-2. Most of the major players has been involved in R&D activities regarding cell signaling pathways. The mortality in most of the COVID-19 patients is due to the presence of a cytokine storm, which is induced by the virus. The excessive production of these proinflammatory cytokines leads to acute respiratory distress syndrome aggravation and widespread tissue damage, which results in multi-organ failure and death. Thus, targeting cell signaling pathways such as cytokines during the management of COVID-19 may lead to the reduction of the mortality rate and improved outcomes. This is likely to have a positive impact on the market studied.
In the United States, for the fiscal year 2018, USD 520 million was granted by the federal government, for the National Cancer Institute (NCI) budget, for breast cancer research, USD 212 million for colorectal cancer research, USD 241 million for leukemia. Additionally, the estimates available on the National Institute of Health portal for stem cell-based research indicate a cumulative funding budget of more than USD 3 billion, for research in various fields of stem cell applications. The need for cell signaling in cancer research plays a vital role in the progressive growth of the cell signaling market in the United States. The growing funding in cancer research and stem cell research are directly causing an increase in the cell signaling research area, particularly in the United States. The increasing trend of increment in research funding is expected to lead to the growth of the market studied in the United States.
The market studied is a moderately consolidated market owing to the presence of the small and large market players. Some of the market players are Beckman Coulter Inc. (Danaher), Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Cell Signaling Technology Inc., Merck KGaA, PerkinElmer Inc., Promega Corporation, Qiagen N.V., and Thermo Fischer Scientific Inc.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Rising Burden of Chronic Diseases
- 4.2.2 Increased Funding for Cell-based Research
- 4.2.3 Technological Advancements in Cell-based Research Instruments
- 4.3 Market Restraints
- 4.3.1 High cost of Cell Signaling Systems
- 4.3.2 Ethical Issues Related to Embryonic Stem Cell Signaling Research
- 4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Signaling Type
- 5.1.1 Endocrine Signaling
- 5.1.2 Paracrine Signaling
- 5.1.3 Autocrine Signaling
- 5.1.4 Synaptic Signaling
- 5.1.5 Other Signaling Types
- 5.2 By Product
- 5.2.1 Instruments
- 5.2.2 Consumables
- 5.3 By Technology
- 5.3.1 Flow Cytometry
- 5.3.2 Mass Spectrometry
- 5.3.3 Western Blotting
- 5.3.4 ELISA
- 5.3.5 Other Technologies
- 5.4 By Pathway
- 5.4.1 AKT Signalling Pathway
- 5.4.2 AMPK Signalling Pathway
- 5.4.3 ErbB/HER Signaling Pathway
- 5.4.4 Other Signaling Pathways
- 5.5 Geography
- 5.5.1 North America
- 184.108.40.206 United States
- 220.127.116.11 Canada
- 18.104.22.168 Mexico
- 5.5.2 Europe
- 22.214.171.124 Germany
- 126.96.36.199 United Kingdom
- 188.8.131.52 France
- 184.108.40.206 Italy
- 220.127.116.11 Spain
- 18.104.22.168 Rest of Europe
- 5.5.3 Asia-Pacific
- 22.214.171.124 China
- 126.96.36.199 Japan
- 188.8.131.52 India
- 184.108.40.206 Australia
- 220.127.116.11 South Korea
- 18.104.22.168 Rest of Asia-Pacific
- 5.5.4 Middle East and Africa
- 22.214.171.124 GCC
- 126.96.36.199 South Africa
- 188.8.131.52 Rest of Middle East and Africa
- 5.5.5 South America
- 184.108.40.206 Brazil
- 220.127.116.11 Argentina
- 18.104.22.168 Rest of South America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Becton, Dickinson and Company
- 6.1.2 Bio-Rad Laboratories Inc.
- 6.1.3 Bio-Techne Corporation
- 6.1.4 Cell Signaling Technology Inc.
- 6.1.5 Danaher Corporation (Beckman Coulter Inc.)
- 6.1.6 Merck KGaA
- 6.1.7 PerkinElmer Inc.
- 6.1.8 Promega Corporation
- 6.1.9 Qiagen NV
- 6.1.10 Thermo Fischer Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS